Ether Compounds for Treatment of Medical Disorders

摘要

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an ether substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

主权项

1. An ether compound selected from:wherein:
(a) A selected from a moiety of FIG. 1 (B or C);
B is selected from a moiety of FIG. 2 (B, C, D or E); FIG. 7 (A, B, C, D or E) or FIG. 8;C is selected from a moiety of FIG. 3 (B, C, D, E, F, G, H, I, J, K, L, M or N) or FIG. 5;L is a bond or selected from a moiety of FIG. 4 (B, C, D, E or F); andR32 is selected from a moiety of FIG. 6 (A, B, or C); (b) A is selected from a moiety of FIG. 1 (D or E);
B is selected from a moiety of FIG. 2 (B, C, D or E);C is selected from a moiety of FIG. 3 (B, C, D, E, F, G, H, I, J, K, L, M or N) or FIG. 5;L is a bond or selected from a moiety of FIG. 4 (B, C, D, E or F); andR32 is selected from a moiety of FIG. 6 (A, B, or C); (c) A is selected from a moiety of FIG. 1 (B, C, D, or E);
B is selected from a moiety of FIG. 2 (B, C, D or E), FIG. 7 (A, B, C, D, or E) or FIG. 8;C is selected from a moiety of FIG. 3 (B, C, D, E, F, G, H, I, J, K, L, M or N);L is a bond or selected from a moiety of FIG. 4 (B, C, D, E or F); andR32 is selected from a moiety of FIG. 6 (A, B, or C); (d) a compound of Table 2; or (e) a compound of FIG. 9 (A, B, C, D, E, F, G or H) wherein Z32 is R32 selected from a moiety of FIG. 6 (A, B or C);
or a pharmaceutically acceptable salt thereof.